Seeking Alpha
 

Albany Molecular Research, Inc. (AMRI)

- NASDAQ
  • Nov. 5, 2014, 12:49 PM
    | Comment!
  • Apr. 9, 2014, 12:45 PM
    | Comment!
  • Mar. 26, 2014, 5:35 PM
    • Essex Property Trust (ESS) +2.2% AH on news it will replace Cliffs Natural Resources (CLF) in the S&P 500 after the close of trading April 1.
    • CLF will move down to the S&P MidCap 400, replacing ESS.
    • FEI Co. (FEIC) will replace BRE Properties (BRE), which is being acquired by Essex, in the MidCap 400, and Fabrinet (FN) will replace FEI in the S&P SmallCap 600.
    • Also, Albany Molecular Research (AMRI) will replace Supertex (SUPX), which is being acquired, in the SmallCap 600.
    • AMRI +4.2%, FEIC +2%, FN +1.5%, CLF -1.3% AH.
    | Comment!
  • Dec. 3, 2013, 10:18 AM
    • Albany Molecular Research (AMRI -10%) slides hard in morning trading.
    • Sterne Agee has cut the shares to Neutral from Buy.
    • Price target is now $12 (from $15).
    • Here's analyst Greg Bolan: "As we have written multiple times, we believe CRO valuations are expensive and therefore have a difficult time seeing AMRI generate a strong return through acquisition(s)."
    | Comment!
  • Aug. 12, 2013, 2:00 PM
    • Albany Molecular Research (AMRI -13.2%) plunges after an SEC filing shows Bristol-Myers (BMY -1.4%) has terminated the development of the triple reuptake inhibitor BMS-820836.
    • According to BMY, the investigational drug failed to show superiority over duloxetine or escitalopram in a Phase II study for Treatment Resistant Depression.
    • AMRI says the news will have "no impact on [its] financial guidance or forecasts." (8-K)
    | Comment!
  • Jun. 12, 2013, 2:44 PM
    The profitability of Albany Molecular's (AMRI +9.9%) "core business could reach historic levels," Sterne Agee says, citing the expected "resurgence in preclinical-PI activity over the next several years." Analyst Greg Bolan resumes coverage at Buy with a $15 price target.
    | Comment!
  • May 7, 2013, 12:52 PM
    Midday top 10 gainers: FSGI +28%. ARCI +27%. ININ +18%. MELI +18%. NLS +18%. PRTS +18%. REED +16%. PODD +14%. LAS +12%. MKTG +12%.
    Midday top 10 losers: DCO -27%. RKUS -25%. GNK -24%. CUTR -23%. ARUN -22%. SNTA -15%. AMRI -12%. PIKE -12%. TA -12%. PTRY -11%.
    | Comment!
  • Feb. 13, 2013, 12:45 PM
    Midday top 10 gainers: RSOL +76%. RCON +27%. TRLA +25%. PRLB +24%. RPXC +22%. PRO +18%. ICAD +17%. PES +13%. AMRI +12%. VG +11%.
    Midday top 10 losers: LTRE -21%. EZCH -21%. RATE -19%. RAX -18%. CLF -18%. MPG -17%. FBN -17%. NAII -16%. ATOS -14%. ZN -13%.
    | Comment!
  • Feb. 12, 2013, 12:45 PM
    Midday top 10 gainers: XRSC +35%. RSOL +31%. STEM +24%. ZIOP +19%. AVP +19%. AMRI +18%. OSBC +16%. DQ +14%. MAS +13%. GILT +12%.
    Midday top 10 losers: KVHI -11%. ATAI -11%. LVLT -11%. CLSN -10%. RBPAA -10%. MELA -10%. RVLT -10%. CBMX -10%. QLYS -9%. APRI -8%.
    | Comment!
  • Feb. 12, 2013, 12:20 PM
    Albany Molecular Research (AMRI +18%) surges after its FQ3 easily blows out estimates this morning. Contract revenue was $59.1M, up 50% from the prior-year period with sequential revenue improvement in Discovery and Large Scale Manufacturing services. Contract margin jumped to 18% from 2% in the prior-year period. The company also forecast an upbeat Q4, now expecting an EPS of $0.08 - $0.12, better than the Street view of $0.06.
    | Comment!
  • Jan. 22, 2013, 12:45 PM
    Midday top 10 gainers: PBIB +32%. DQ +18%. TECUA +18%. ONP +17%. USEG +17%. RDCM +17%. CIMT +14%. BOX +14%. MTRX +12%. PRCP +12%.
    Midday top 10 Losers: CALI -12%. OIBR -12%. BVX -10%. DOM -9%. ARNA -8%. IIVI -8%. AMRI -8%. UPI -8%. IPXL -8%. EXFO -7%.
    | Comment!
  • Nov. 6, 2012, 10:30 AM
    Albany Molecular Research (AMRI +11%) pops after beating on its Q3 bottom line this morning. Total sales were up 11.2% Y/Y on stronger royalty and contract revenues, particularly in its large-scale manufacturing segment. The company also boosts its outlook for FY12 as well as Q4. It now sees FY12 earnings coming in between $0.10 and $0.16 per share, towards the top-end of the Street's $0.12 consensus, and for Q4, its EPS is targeted to be $0.08 to $0.12, also better than the Street view of $0.06.
    | Comment!
  • Feb. 7, 2012, 8:15 AM
    Albany Molecular Research (AMRI): Q4 EPS of -$0.19 misses by $0.05. Revenue of $46.6M (-4.1% Y/Y) misses by $2M. Shares -8.8% premarket. (PR)
    | Comment!
Visit Seeking Alpha's
AMRI vs. ETF Alternatives
Company Description
Albany Molecular Research Inc is a contract research and manufacturing organization providing customers drug discovery, development and manufacturing services.
Sector: Services
Country: United States